NCT03575325 - Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

June 7, 2021

Study Completion Date

September 14, 2023

Conditions

Lymphoid LeukemiaAcute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic Leukemia

Interventions

DRUG

CPX-351

The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa